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L ung transplantation has become an established ther-apeutic option for end-stage pulmonary disease.1
Ischemia/reperfusion injury remains the major problem
in the early phase after lung transplantation. Improved
preservation and flushing technique have reduced mor-
bidity of early graft dysfunction; however, severe
ischemia/reperfusion injury still occurs in 10% of lung
transplant recipients.
The pathophysiology of this type of injury has been
extensively studied. Therapeutic strategies blocking only
one of the redundant pathways of the nonspecific immune
response showed limited success.2-5 Therefore, combined
treatment suppressing more than one of the mediators of
ischemia/reperfusion injury seems more promising.
The complement system as a part of the humoral first
line of defense and a primary mediator of the inflam-
Background: The nonspecific immune response with activation of the com-
plement system and polymorphonuclear leukocytes is important for the
mediation of reperfusion injury after lung transplantation. In this study, we
investigated the combined blockade of the complement system and leuko-
cyte adhesion by a novel drug combining soluble complement receptor type
1 (sCR1, CD35) with the selectin ligand sialyl Lewis X (sLeX, CD15s) syn-
thesized to sCR1sLeX. Both sCR1 and sCR1sLeX were supplied by AVANT
Immunotherapeutics, Inc, Needham, Massachusetts.
Methods: Orthotopic allogeneic single left lung transplantation was per-
formed in male rats (Brown Norway to Fischer F344; n = 5 in all groups)
after a total ischemic time of 20 hours. Recipients received either no specif-
ic treatment (control) or administration of sCR1 (10 mg/kg) or sCR1sLeX
(10 mg/kg) 15 minutes before reperfusion by intracardiac injection. Twenty-
four hours after reperfusion, the native contralateral lung was occluded to
assess gas exchange of the graft only. In additional animals (5 per group),
lung tissue was frozen 24 hours after reperfusion and assessed for myeloper-
oxidase activity as a measurement of neutrophil migration into the graft and
thiobarbituric acid reactive substances to quantify lipid peroxidation.
Results: Graft function as assessed by arterial PO2 in recipients treated with
sCR1sLeX was superior not only to that of controls (383 ± 53 vs 56 ± 7 mm Hg,
P = .000095) but also to that of animals treated with sCR1 (243 ± 45 mm Hg,
P = .031). This improvement was confirmed by significant reduction of neutrophil
migration (0.33 ± 0.05 vs control, 1.0 ± 0.09 ∆OD/mg/min, P = .0000024) and lipid
peroxidation (6.2 ± 0.38 vs control, 10.6 ± 0.54 pmol/g, P = .00021).
Conclusions: Our data indicate that combined inhibition of complement acti-
vation and leukocyte adhesion with sCR1sLeX reduces reperfusion injury sig-
nificantly and that both mechanisms are effectively inhibited in this model. 
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matory process is one of the major pathways leading to
severe graft dysfunction following reperfusion after
prolonged ischemia. In post-transplantation lung
ischemia/reperfusion, complement activation may
accelerate tissue injury either directly by complement
factors or indirectly by complement-mediated neu-
trophil activation.
A long series of studies demonstrates that neutrophils
contribute to the vascular dysfunction and permeability
in the initial phase after reperfusion. sCR1sLex
(AVANT Immunotherapeutics, Inc, Needham, Mass)
combines the effect of human soluble complement
receptor type 1 (sCR1) and sialyl Lewis X (sLex) in one
molecule. It blocks complement activation and reduces
leukocyte-endothelial adhesion.6 In this study, the
effect of sCR1sLex on post-transplantation graft func-
tion was evaluated in a small animal model of allo-
geneic single left lung transplantation after prolonged
ischemia in comparison with untreated controls and
recipients receiving sCR1 only.
Materials and methods
Weight-matched (200-250 g) male rats (donors: Brown
Norway; recipients: Fischer F344) underwent orthotopic sin-
gle left lung allotransplantation with a cuff technique used for
the vessel anastomoses7 and a conventional running suture for
the bronchial anastomosis.
All animals received humane care in compliance with the
European Convention of Animal Care. The protocol was
approved by the local animal study committee.
Donor procedure. Each animal was anesthetized by
intraperitoneal administration of pentobarbital (50 mg/kg) and
was heparinized (500 IU/kg). A tracheotomy was carried out
and the lungs were ventilated through a cannula (FIO2 = 1.0) by
a Harvard rodent ventilator (Harvard Apparatus, South Natick,
Mass) at a tidal volume of 10 mL/kg. After division of the infe-
rior vena cava and resection of the left appendix of the heart, a
small silicone tube was inserted into the main pulmonary artery.
Both lungs were flushed with 20 mL of low-potassium dextran
solution (Perfadex; Xvivo, Göteborg, Sweden)8 at a pressure of
20 cm H2O. The trachea was tied in end-inspiration. The heart-
lung block was removed and 14-gauge cuffs were placed
around the pulmonary artery and vein. The vessels were invert-
ed and tied onto the cuff. The lung was stored in low-potassium
dextran solution at 4°C until implantation.
Recipient procedure. Transplantation was performed after
20 hours of cold ischemia (4°C). The recipient was anes-
thetized by breathing halothane in a glass chamber followed
by intubation. Anesthesia was maintained with 2% halothane.
A left lateral thoracotomy was performed in the fourth inter-
costal space. The left hilum was dissected. After the pul-
monary artery and vein had been clamped with removable
microclips, the pulmonary vein was opened, flushed with
heparinized saline solution, and the cuff was inserted and
fixed with 6-0 silk. In the same technique, the pulmonary
artery was anastomosed. The native left lung was removed
and the bronchial anastomosis performed with a running
over-and-over stitch with 9-0 Monosof suture (Tyco
Healthcare, Wollerau, Switzerland). The lung was first reven-
tilated and then reperfused. A chest tube was inserted and the
thoracotomy closed. The chest tube was removed after
restoration of spontaneous breathing.
Assessment. The recipient animal was anesthetized by
intraperitoneal administration of pentobarbital (50 mg/kg
body weight).
Arterial blood gas analysis. Recipients were put to death
24 hours after reperfusion. Each animal was ventilated with
an FIO2 of 1.0, a frequency of 100 breaths/min, and a tidal
volume of 8 mL/kg body weight by a tracheotomy. For func-
tional assessment of the transplanted left lung, the right hilum
was dissected and the right pulmonary artery and right main
bronchus were occluded with microvessel clips. Five minutes
after occlusion, a steady state was reached and an arterial
blood gas sample was drawn from the thoracic aorta.
Myeloperoxidase activity (MPO) and thiobarbituric acid
reactive substances (TBARS). Ventilation was the same as in
donors. In these animals the lungs were flushed with 20 mL
of saline solution through the pulmonary artery 24 hours after
reperfusion. The transplanted lung was removed and snap-
frozen in liquid nitrogen.
Study groups. In each group, 5 animals underwent trans-
plantation for the evaluation of lung function by arterial
blood gas analysis. In separate animals (n = 5/group), trans-
plantation was done for the assessment of MPO and lipid per-
oxidation (TBARS).
Group I served as the control group, with no specific treat-
ment. In group II recipients were treated with sCR1 (10
mg/kg), and in group III recipients received 10 mg/kg
sCR1sLex. Both sCR1 and sCR1sLex were generously provid-
ed by AVANT Immunotherapeutics, Inc. Drugs were adminis-
tered by intracardiac injection 15 minutes before reperfusion.
For normal values of MPO and TBARS in rat lung, tissue sam-
ples of 4 animals were frozen directly after harvest.
Blood gas analysis. For assessment of arterial PO2, a blood
gas analyzer (AVL 993, AVL List GmbH, Graz, Austria) was
used.
MPO assay. Lung samples were snap-frozen in liquid
nitrogen and stored at –70°C until assay. Quantitative MPO
activity was determined as previously described.9 The frozen
lung tissue (100 mg) was homogenized in 1 mL of 0.5%
Table I. Warm ischemic time during implantation in
all groups
Groups
Arterial PO2 (min) MPO, TBARS (min)
Control 20.8 ± 0.58 20.6 ± 0.8
SCR1 20.6 ± 0.51 20.6 ± 0.7
P = .775 vs control P = 1.0 vs control
SCR1sLex 20.0 ± 0.32 19.4 ± 1.0 
P = .264 vs control P = .283 vs control
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hexadecyltrimethylammonium bromide, 5 mmol/L ethylene-
diaminetetraacetic acid, and 50 mmol/L potassium phosphate
buffer (pH 6.2) with a tissue grinder. The homogenate was
centrifuged at 10,000g for 15 minutes at 4°C. The super-
natant was assayed for total soluble protein by the method of
Pierce Laboratories10 and for MPO activity. Enzyme activity
was measured spectrophotometrically. Then, 10 mg of 5-fold
supernatant was combined with 0.6 mL Hanks bovine serum
albumin solution, 0.5 mL of 100 mmol/L potassium phos-
phate buffer (pH 6.2), 0.1 mL of 0.05% H2O2, and 0.1 mL of
Fig 1. Arterial PO2 (mm Hg) of the graft 24 hours after reperfusion (mean ± SEM).
Fig 2. Myeloperoxidase activity (∆OD/mg/min) as measurement of neutrophil migration into the graft 24 hours after
reperfusion (mean ± SEM).
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1.25 mg/mL o-dianisidine. Color development was stopped
by addition of 1% NaN3 after either 5 or 20 minutes at room
temperature. The optical density was measured at 460 nm
with a spectrophotometer (Kadas 100; Dr Lange AG, Zurich,
Switzerland). Color development from 5 to 20 minutes was
linear. Enzyme activity is expressed as change in optical den-
sity unit per milligram of tissue protein per minute
(∆OD/mg/min).
TBARS. Donor and recipient lung samples were frozen
immediately and stored at –70°C until assay. TBARS were
measured according to the method of Ohkawa, Ohishi, and
Yagi11 in 10% wet weight per volume homogenate.
Aliquots (0.2 mL) of this homogenate were added to tubes
containing 0.2 mL of 8.1% sodium dodecyl sulfate, 1.5 mL
of 20% acetic acid solution adjusted to pH 3.5 with sodium
hydroxide, and 1.5 mL of 0.8% solution of thiobarbituric
acid. The mixture was brought to a volume of 4 mL by the
addition of distilled water, heated at 95°C for 60 minutes,
and then cooled with tap water. Next, 1 mL of distilled
water and 5 mL of butanol/pyridine (15:1) were added (all
chemicals by Fluka Chemie AG, Buchs, Switzerland). The
solution was centrifuged at 4000 rpm for 10 minutes. The
absorbance of the upper layer was measured at 532 nm with
a spectrophotometer (Kadas 100; Dr Lange AG, Zurich,
Switzerland). The TBARS levels were determined by refer-
ence to a standard curve of 1,1,3,3-tetramethoxypropane
(Fluka Chemie AG, Buchs, Switzerland), and the results
were expressed as picomoles of malondialdehyde per gram
of wet lung.
Statistical analysis. All values are given as the mean ±
standard error of the mean (SEM). Analysis of variance with
planned comparison (contrast vectors) between the groups
was applied. The STATISTICA 4.5 software (StatSoft, Tulsa,
Okla) was used.
Results
Warm ischemic time in all transplantation groups
was between 19.4 ± 1.0 and 20.8 ± 0.58 minutes, with
no significant difference between groups (Table I).
Three recipients in the control group and 1 animal
treated with sCR1 had severe edema with aspiration to
the contralateral side and died within the first 3 hours
after transplantation. One recipient in group III died of
technical problems regarding the bronchial anastomo-
sis. All these animals were excluded from analysis.
Blood gas analysis. Twenty-four hours after reperfu-
sion, arterial PO2 was very low in control animals
(group I, 56 ± 7 mm Hg). Treatment with sCR1sLex
resulted in better graft function than in controls (383 ±
53 mm Hg, P = .000095) (Fig 1). Administration of
sCR1 improved gas exchange to a significantly lesser
extent than sCR1 sLex (243 ± 45 mm Hg, P = .0066 vs
control; P = .031 vs sCR1 sLex).
MPO assay. In grafts of recipients that did not
receive any specific treatment, neutrophil migration as
indicated by MPO assay was significantly elevated in
Fig 3. TBARS levels (pmol/g) in allograft tissue as measurement of lipid peroxidation 24 hours after reperfusion
(mean ± SEM).
comparison with native lungs frozen immediately after
harvest (1.03 ± 0.087 vs 0.22 ± 0.047 ∆OD/mg/min,
P = .000001) (Fig 2). Treatment with sCR1sLex result-
ed in significant reduction of MPO activity (0.33 ±
0.051 ∆OD/mg/min, P = .0000024 vs control). In grafts
treated with sCR1, a reduction of MPO activity to a
lesser degree was noted (0.48 ± 0.074 ∆OD/mg/min,
P = .000036 vs control; P = .14 vs sCR1sLeX).
Interestingly, the difference between lung tissue
frozen after harvest and grafts that received sCR1 was
statistically significant (P = .025), whereas only a slight
elevation of MPO activity was noted in group III
(sCR1sLeX, P = .33).
TBARS. Lipid peroxidation was significantly elevat-
ed in control animals 24 hours after reperfusion as
compared with lung tissue assessed directly after har-
vest (10.65 ± 0.54 vs 3.94 ± 0.75 pmol/g, P = .000005)
(Fig 3). Grafts of recipients treated with sCR1 revealed
a distinct reduction of TBARS (8.32 ± 0.89 pmol/g,
P = .022 vs control). Treatment with sCR1sLex reduced
lipid peroxidation significantly not only compared with
controls (6.23 ± 0.38 pmol/g, P = .00021) but also com-
pared with recipients that received sCR1 (P = .037).
Discussion
In this model of unilateral left lung transplantation in
rats after prolonged ischemia, sCR1sLex significantly
improves gas exchange of the graft 24 hours after
reperfusion compared with either untreated controls or
recipients treated with sCR1. Reperfusion injury in
lungs treated with sCR1sLex was significantly reduced,
as substantiated by less neutrophil influx and reduction
of tissue injury mediated by oxygen-derived free radi-
cals. This study may indicate that the combined inhibi-
tion, in contrast to inhibition of a single proinflamma-
tory pathway, is a promising strategy to reduce
post-transplantation lung ischemia/reperfusion injury.
Complement is a proteolytic cascade system interact-
ing with cells and is present in the blood plasma and
other body fluids of all vertebrates. It mediates an
inflammatory response by production of specific pep-
tides with anaphylactic or chemotactic activity and the
interaction with specific complement receptors on cell
surfaces. The innate immune response is amplified by
products of the complement components C3 and C5,
which cause an increase in vascular permeability (C3a,
C5a), leukocyte adhesion, and subsequent migration.
Complement stimulates the synthesis of different
proinflammatory cytokines. The final product of com-
plement activation, the membrane attack complex,
leads to direct membrane damage in target cells.
Complement receptor type 1 (CR1, CD35, C3b/C4b
receptor) is a transmembrane glycoprotein expressed
on erythrocytes and virtually all leukocytes. On phago-
cytes, CR1 is involved in the initial binding of particles
coated with activated complement component 3 (C3b),
which are subsequently ingested. CR1 is not only a cel-
lular receptor, but also the most potent inhibitor of both
the classical and alternative pathways of complement
activation. Activated neutrophils and macrophages
shed the extracellular portion of CR1 (soluble CR1,
sCR1).12 It is more than 100-fold more effective than
any other soluble complement regulatory proteins, for
example, factor H, the physiologic cofactor for inacti-
vation of C3b in plasma.13,14 Soluble CR1 accelerates
the decay of the C3/C5 convertase complexes and par-
ticipates in the degradation of C3b and C4b.13
Inhibition of complement activation by administration
of sCR1 protects against lung injury in different mod-
els of acute inflammatory response.15 The inhibition of
the nonspecific immune response after ischemia/reper-
fusion by administration of sCR1 in a model of
myocardial infarction in rats demonstrated a beneficial
effect.14 Administration of sCR1 during unilateral lung
transplantation in swine after prolonged ischemia com-
pletely inhibited complement activity and significantly
reduced reperfusion edema, indicating the important
role of complement activation for the development of
ischemia/reperfusion injury.16 The relevance of these
findings has been confirmed recently by a clinical mul-
ticenter trial in patients undergoing lung transplanta-
tion.17
Complement mediates activation and migration of
neutrophils by C5a. Therefore, complement exerts the
post-transplantation reperfusion injury not only by its
effector proteins but also by stimulation of polymor-
phonuclear leukocytes. Besides β-integrins and mem-
bers of the immunoglobulin supergene family, selectins
are adhesion molecules initiating leukocyte migration.
These adhesion molecules are up-regulated in a num-
ber of different lung injuries. Specific inhibitors of neu-
trophil adhesion such as monoclonal antibodies and
selectin ligands18 and inhibitors of neutrophil selectin
up-regulation as leumedins have been shown to reduce
post-transplantation lung reperfusion injury in animal
studies. In a rat model, combined administration of
monoclonal antibodies against intracellular adhesion
molecule-1, CD11a, and CD18 resulted in superior gas
exchange 24 hours after reperfusion and reduced accu-
mulation of neutrophils in the lung tissue.19 Blockade
of P-selectin by an anti–P-selectin immunoglobulin G
antibody improved graft function and reduced poly-
morphonuclear leukocyte infiltration after rat lung
transplantation.20
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The oligosaccharide sLex is a ligand common to all
selectins and therefore an attractive compound for the
inhibition of selectin-dependent neutrophil adhesion. In
a canine model of left lung allotransplantation after
prolonged ischemia, administration of the carbohydrate
sLex analog CY-1503 improved the graft’s gas
exchange (P < .01) and reduced neutrophil migration as
assessed by MPO assay and neutrophil count in bron-
choalveolar lavage fluids.21
Recently, the glycoprotein product sCR1sLex has
been synthesized by covalent post-translational modi-
fication of sCR1 with sLeX glycosylation in a mam-
mal cell line.6 sCR1sLex maintains the complement
blocking activity of sCR1, blocks P-selectin–mediat-
ed cellular adhesion, and binds to cell surface E-
selectin in vitro. In vivo, its effects on experimental
stroke and myocardial infarct size have been studied:
Zacharowski and colleagues22 subjected Wistar rats to
30 minutes of ischemia of the left anterior descending
coronary artery, followed by 2 hours of reperfusion.
Treatment with either sCR1 or sCR1sLex resulted in
reduction of infarct size and less release of troponin T
from injured myocytes. There was no clear superiori-
ty of sCR1sLex as compared with sCR1 alone; how-
ever, a longer ischemic time and reperfusion period
might have emphasized the trend to a better improve-
ment. In experimental cerebral ischemia in mice, pre-
treatment with sCR1sLex reduced infarct volume up
to 11-fold in a dose-dependent manner and decreased
intracerebral hemorrhage and neurologic deficit 24
hours after stroke.23 Infusion of sCR1 led to less
reduction in infarct size and higher neurologic impair-
ment. Interestingly, administration of both drugs after
the onset of ischemia at the time of reperfusion also
improved outcome, but to a lesser degree. Taking into
account the clinical situation, in which treatment
would probably be performed after the onset of reper-
fusion injury, further studies are needed to evaluate
the effect of sCR1sLex in already established lung
ischemia/reperfusion injury.
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